News | January 21, 2026

Kardium Publishes Trial Results for Globe Pulsed Field System

This study evaluated the Globe Pulsed Field System by Kardium for the treatment of paroxysmal atrial fibrillation.

Kardium Publishes Trial Results for Globe Pulsed Field System

Photo: Kardium Inc.


Jan. 20, 2026 — Kardium Inc. has announced the publication of the PULSAR clinical trial results in the Journal of the American College of Cardiology (JACC). This study evaluated the Globe Pulsed Field System by Kardium for the treatment of paroxysmal atrial fibrillation (PAF).

The multicenter pivotal trial demonstrated that the Globe System achieved durable pulmonary vein isolation (PVI) in 95% of veins with only one pulsed field application, while maintaining a 0% device-related primary safety event rate. At 12 months, 78% of patients remained free from atrial arrhythmias, further underscoring the effectiveness of the system in treating drug-refractory PAF.

“The Globe Pulsed Field System has the potential to transform how we treat atrial fibrillation by delivering durable pulmonary vein isolation with remarkable efficiency and safety,” said Dr. Vivek Reddy, Principal Investigator of the trial. “These results show that this technology can make a real difference for patients, offering them better outcomes and a safer path to long term relief from arrhythmias.”

"The PULSAR pivotal trial highlights how the Globe Pulsed Field System can deliver consistent, durable outcomes with an exceptional safety profile. These results represent an important step forward in advancing treatment options for patients with paroxysmal atrial fibrillation, and we are proud to share this work with the global cardiology community,” said Dr. Atul Verma, Co-Principal Investigator of the trial.

“The publication of the PULSAR pivotal trial results in JACC is a tremendous validation of the safety, efficacy and efficiency of the Globe System. At Kardium, we are committed to delivering the most advanced system for the treatment of atrial fibrillation,” said Kevin Chaplin, Chief Executive Officer of Kardium.

The study enrolled 183 patients across leading centers in North America and Europe, with procedures showing efficiency in mapping, ablation, and overall treatment times.

The PULSAR pivotal IDE trial (NCT05462145) evaluated the safety and effectiveness of the Globe Pulsed Field System in patients with symptomatic paroxysmal atrial fibrillation. The study was sponsored by Kardium Inc. and conducted at 12 international centers with leading electrophysiologists.


Additional Content

Feature | EP Lab | Lars Thording, PhD

Medical device portfolios now move on two very different clocks. New technologies can gain clinical adoption within ...

Home October 14, 2026
Home
News | EP Lab

July 7, 2026 —AtaCor Medical has announced the enrollment of the first patient in the company's ALARION-EV trial ...

Home July 09, 2026
Home
News | EP Lab

April 17, 2026 — Corify Care has announced that the U.S. Food and Drug Administration (FDA) has granted clearance for ...

Home April 20, 2026
Home
News | EP Lab

Jan. 28, 2026 — Corify Care has announced a major development in cardiac electrophysiology with the publication of its ...

Home January 29, 2026
Home
News | EP Lab

April 22, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home April 29, 2025
Home
Subscribe Now